医学
胎盘生长因子
子痫前期
妊娠期
食品药品监督管理局
可溶性fms样酪氨酸激酶-1
叙述性评论
疾病
不利影响
胎盘
产科
胎儿
怀孕
内科学
重症监护医学
血管内皮生长因子
血管内皮生长因子受体
药理学
遗传学
生物
作者
Richard M. Burwick,M. Hellen Rodriguez
标识
DOI:10.1097/aog.0000000000005532
摘要
Preeclampsia contributes disproportionately to maternal and neonatal morbidity and mortality throughout the world. A critical driver of preeclampsia is angiogenic imbalance, which is often present weeks to months before overt disease. Two placenta-derived angiogenic biomarkers, soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), have proved useful as diagnostic and prognostic tests for preeclampsia. Recently, the U.S. Food and Drug Administration approved the sFlt-1/PlGF assay to aid in the prediction of preeclampsia with severe features among women with hypertensive disorders of pregnancy at 24-34 weeks of gestation. In this narrative review, we summarize the body of work leading to this approval and describe how the sFlt-1/PlGF ratio may be implemented in clinical practice as an adjunctive measure to help optimize care and to reduce adverse outcomes in preeclampsia.
科研通智能强力驱动
Strongly Powered by AbleSci AI